Brief: Bavarian Nordic Raises Revenue, EBITDA Margin Forecasts
BRIEF-Bavarian Nordic Raises Revenue, EBITDA Margin Forecasts Oct 8 (Reuters) - Bavarian Nordic A/S BAVA.CO:
BAVARIAN NORDIC UPGRADES FULL-YEAR 2026 FINANCIAL GUIDANCE AFTER STRONG TRAVEL HEALTH PERFORMANCE
REVENUE AND EBITDA MARGIN EXPECTATIONS INCREASED, DRIVEN BY STRONGER-THAN-EXPECTED TRAVEL HEALTH SALES
EXPECTS 2026 TRAVEL HEALTH REVENUE OF DKK 3.40 BILLION, UP FROM DKK 3 BILLION
ALL OTHER REVENUE ASSUMPTIONS REMAIN UNCHANGED
INCREASE IS PRIMARILY DRIVEN BY HIGHER RABIES VACCINE SALES, PARTICULARLY IN UNITED STATES
Source text: ID:nGNE9tR3Dj
Further company coverage: BAVA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Completes First Tranche Of Share Buy-Back Program
Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government
Brief: Bavarian Nordic Awarded Multi-Year Vaccine Contract By UK Government
Bavarian Nordic donates 75,000 mpox vaccine doses to global emergency stockpile
Brief: Bavarian Nordic Donates To Global Mpox Emergency Stockpile